# PMV Pharmaceuticals, Inc. (PMVP) — capital_raise/public_offering [pending]
Source: sec.gov · situation sit_543ffdc86a16d6d1d5ee · public 2478602984851765407 · retrieved 2026-09-02T23:43:37.586Z

## Overview
PMV Pharmaceuticals, Inc. is a pharmaceutical company developing rezatapopt for the treatment of patients with platinum-resistant/refractory ovarian cancer harboring a TP53 Y220C mutation.

PMV Pharmaceuticals entered into an underwriting agreement with TD Securities (USA) LLC on August 31, 2026, for an underwritten offering of 22,055,000 shares of common stock, 19,900,000 pre-funded warrants to purchase common stock, and 41,955,000 common stock warrants. Common shares and pre-funded warrants were each sold with accompanying common stock warrants at combined offering prices of $1.21 per share and $1.20999 per pre-funded warrant, respectively. The company estimates net proceeds of approximately $47.0 million after deducting underwriting discounts and commissions. The offering is expected to close on September 2, 2026, subject to customary closing conditions.

## Terms
- Counterparty: TD Securities (USA) LLC · Deal value: $47.0M · Consideration: mixed · Price/share: $1.21

## Key dates
- Announced 2026-09-01 · Expected close 2026-09-02

## Timeline
- 2026-09-01 · 8-K (0001193125-26-378838): 8-K - PMV Pharmaceuticals, Inc. — *PMV Pharmaceuticals, Inc. is a pharmaceutical company developing rezatapopt for the treatment of patients with platinum-resistant/refractory ovarian cancer harboring a TP53 Y220C mutation.* PMV Pharmaceuticals entered into an underwriting agreement with TD Securities (USA) LLC on August 31, 2026, for an underwritten offering of 22,055,000 shares of common stock, 19,900,000 pre-funded warrants to purchase common stock, and 41,955,000 common stock warrants. Common shares and pre-funded warrants were each sold with accompanying common stock warrants at combined offering prices of $1.21 per share and $1.20999 per pre-funded warrant, respectively. The company estimates net proceeds of approximately $47.0 million after deducting underwriting discounts and commissions. The offering is expected to close on September 2, 2026, subject to customary closing conditions.
  https://www.sec.gov/Archives/edgar/data/1699382/0001193125-26-378838.txt

## Citations
- 0001193125-26-378838 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526378838